Advertisement

InFo Hämatologie + Onkologie

, Volume 22, Issue 9, pp 24–29 | Cite as

Schwerpunkt nichtkleinzelliges Lungenkarzinom

Systemtherapie des metastasierten NSCLC

  • Marlitt HornEmail author
Schwerpunkt
  • 17 Downloads

In den letzten Jahren hat sich sehr viel in der Therapie des fortgeschrittenen NSCLC getan. Das liegt vor allem an der Detektion und zielgerichteten Therapie molekularer Aberrationen sowie am Erfolg der Immuntherapie. Dieser Artikel soll Ihnen einen kurzen Überblick darüber geben, wie Patienten mit fortgeschrittenen metastasierten NSCLC aktuell behandelt werden.

Literatur

  1. 1.
    Malvezzi M et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;26(4):779–86CrossRefPubMedGoogle Scholar
  2. 2.
    Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50CrossRefPubMedGoogle Scholar
  3. 3.
    Scagliotti GV et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51CrossRefGoogle Scholar
  4. 4.
    Schiller JH et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8CrossRefPubMedGoogle Scholar
  5. 5.
    Gazdar AF et al. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 2010;29(1):37–48CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Hirsch FR et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388(10048):1012–24CrossRefPubMedGoogle Scholar
  7. 7.
    Shaw AT et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–71CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31(31):3987–96CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gandhi L et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078–92CrossRefGoogle Scholar
  10. 10.
    Gadgeel SM et al. KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. ASCO. 2019;Abstr. 9013Google Scholar
  11. 11.
    Socinski MA et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301CrossRefGoogle Scholar
  12. 12.
    Papadimitrakopoulou V et al. IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC. J Thorac Oncol. 2019;13(10_Suppl):332–3Google Scholar
  13. 13.
    West H et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–37CrossRefPubMedGoogle Scholar
  14. 14.
    Reck M et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–33CrossRefGoogle Scholar
  15. 15.
    Paz-Ares L et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040–51CrossRefPubMedGoogle Scholar
  16. 16.
    Jotte RM et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. ASCO. 2018;Abstr LBA9000.Google Scholar
  17. 17.
    Antonia SJ et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342–50CrossRefPubMedGoogle Scholar
  18. 18.
    Borghaei H et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Brahmer J et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123–35CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Rittmeyer A et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65CrossRefPubMedGoogle Scholar
  21. 21.
    Herbst RS et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.LungenClinic Grosshansdorf GmbHGroßhansdorfDeutschland

Personalised recommendations